Vertex's HCV Drug Might Gain Advantage Over Merck's From FDA Draft Guidance
Executive Summary
FDA’s draft guidance on chronic hepatitis C drug development inspired one analyst to predict an advantage for Vertex Pharmaceuticals’ telaprevir over Merck & Co.’s boceprevir.
You may also be interested in...
Third Telaprevir Pivotal Study Raises Bar For Competitors Another Notch
Collective top-line data from the Phase III program testing Vertex Pharmaceuticals' protease inhibitor telaprevir in treatment-naïve and treatment-experienced hepatitis C patients set a high bar for competitors, particularly for Merck & Co.'s boceprevir, with which telaprevir is dueling to be the first approved specifically targeted antiviral therapy for hepatitis C (STAT-C).
US FDA Investigating Concomitant Flu, COVID Vaccine Link To Stroke Safety Signal
No stroke risk has been identified, but FDA and CDC officials want to investigate whether concomitant administration of influenza and COVID-19 vaccines are related to the issue.
Inside US FDA’s Return To In-Person Meetings
In an interview, OND Deputy Director of Operations Kevin Bugin describes how FDA might be able to "accelerate" the transition back to in-person meetings if the initial phase with Type A and BPD Type 1 meetings goes well. But there is still no plan to return to in-person advisory committees.